<H1>Chapter DOI: 10.1007/978-1-60327-829-4_9<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>52</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>51</td></tr><tr><td>BibStructured Count</td><td width="10%">49</td></tr><tr><td>BibUnstructured Count</td><td width="10%">3</td></tr><tr><td>DOI already available in SpringerLink</td><td>44</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_9</td><td>BibArticle</td><td>McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 2008;22:373&#8211;88.</td><td><a href=http://dx.doi.org/10.1016/j.beem.2008.02.006>10.1016/j.beem.2008.02.006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_9</td><td>BibArticle</td><td>Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem 1968;243:5953&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_9</td><td>BibArticle</td><td>Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25&#8211;61.</td><td><a href=http://dx.doi.org/10.1146/annurev.bi.63.070194.000325>10.1146/annurev.bi.63.070194.000325</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_9</td><td>BibArticle</td><td>Huggins C, Hodges CV. Studies on prostate cancer, I: the effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293&#8211;7.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.3322/canjclin.22.4.232>10.3322/canjclin.22.4.232</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR5_9</td><td>BibArticle</td><td>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238&#8211;44.</td><td><a href=http://dx.doi.org/10.1001/jama.294.2.238>10.1001/jama.294.2.238</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_9</td><td>BibArticle</td><td>McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003;61:3&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(02)02393-2>10.1016/S0090-4295(02)02393-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_9</td><td>BibArticle</td><td>Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU Int 2008;101:1096&#8211;100.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2007.07374.x>10.1111/j.1464-410X.2007.07374.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_9</td><td>BibArticle</td><td>Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157&#8211;67.</td><td><a href=http://dx.doi.org/10.1038/ncpendmet0399>10.1038/ncpendmet0399</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_9</td><td>BibArticle</td><td>Limonta P, Montagnani MM, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10:709&#8211;20.</td><td><a href=http://dx.doi.org/10.1517/13543784.10.4.709>10.1517/13543784.10.4.709</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_9</td><td>BibArticle</td><td>van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008;71:1001&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2007.12.070>10.1016/j.urology.2007.12.070</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_9</td><td>BibArticle</td><td>Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58:5&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(01)01235-3>10.1016/S0090-4295(01)01235-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_9</td><td>BibArticle</td><td>Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321:413&#8211;8.</td><td><a href=http://dx.doi.org/10.1056/NEJM198908173210701>10.1056/NEJM198908173210701</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_9</td><td>BibArticle</td><td>Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_9</td><td>BibArticle</td><td>Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41&#8211;51.</td><td><a href=http://dx.doi.org/10.1038/ng1935>10.1038/ng1935</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_9</td><td>BibArticle</td><td>Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001&#8211;15.</td><td><a href=http://dx.doi.org/10.1200/JCO.2002.10.018>10.1200/JCO.2002.10.018</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_9</td><td>BibArticle</td><td>Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021&#8211;4.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(00)00793-7>10.1016/S0090-4295(00)00793-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_9</td><td>BibArticle</td><td>Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004;14:177&#8211;83.</td><td><a href=http://dx.doi.org/10.1097/00042307-200405000-00007>10.1097/00042307-200405000-00007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_9</td><td>BibArticle</td><td>Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154&#8211;64.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041943>10.1056/NEJMoa041943</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_9</td><td>BibArticle</td><td>Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007;14:247&#8211;54.</td><td><a href=http://dx.doi.org/10.1097/MED.0b013e32814db88c>10.1097/MED.0b013e32814db88c</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_9</td><td>BibArticle</td><td>Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am 2006;20:909&#8211;23.</td><td><a href=http://dx.doi.org/10.1016/j.hoc.2006.03.013>10.1016/j.hoc.2006.03.013</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_9</td><td>BibArticle</td><td>Fowler FJ, Jr., McNaughton CM, Walker CE, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002;95:287&#8211;95.</td><td><a href=http://dx.doi.org/10.1002/cncr.10656>10.1002/cncr.10656</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_9</td><td>BibArticle</td><td>Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042&#8211;9.</td><td><a href=http://dx.doi.org/10.1210/jc.2007-2595>10.1210/jc.2007-2595</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_9</td><td>BibArticle</td><td>The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235&#8211;46.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.1997.d01-6840.x>10.1046/j.1464-410X.1997.d01-6840.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_9</td><td>BibArticle</td><td>Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781&#8211;8.</td><td><a href=http://dx.doi.org/10.1056/NEJM199912093412401>10.1056/NEJM199912093412401</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_9</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Messing</span> <span style='background:#DDDDDD'>EM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Manola</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sarosdy</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wilding</span> <span style='background:#DDDDDD'>G</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Crawford</span> <span style='background:#DDDDDD'>ED</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Trump</span> <span style='background:#DDDDDD'>D.</span></span></aug> <span style='background:#FF9933'>Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenoectomy in men with node-positive prostate cancer: results at 10 years of EST 3886</span>. In: <span style='background:#FFD9B3'>American Urological Association meeting</span>. <span style='background:#C0FFC0'>Chicago, IL</span>; <span style='background:#66FF66'>2003</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26_9</td><td>BibArticle</td><td>Schroder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European organisation for the research and treatment of Cancer 30846 &#8211; a phase III study. J Urol 2004;172:923&#8211;7.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000135742.13171.d2>10.1097/01.ju.0000135742.13171.d2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_9</td><td>BibArticle</td><td>Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004;22:4109&#8211;18.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.11.514>10.1200/JCO.2004.11.514</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_9</td><td>BibArticle</td><td>Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891. J Clin Oncol 2006;24:1868&#8211;76.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.04.7423>10.1200/JCO.2005.04.7423</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_9</td><td>BibArticle</td><td>Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173&#8211;81.</td><td><a href=http://dx.doi.org/10.1001/jama.300.2.173>10.1001/jama.300.2.173</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_9</td><td>BibArticle</td><td>Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591&#8211;7.</td><td><a href=http://dx.doi.org/10.1001/jama.281.17.1591>10.1001/jama.281.17.1591</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_9</td><td>BibArticle</td><td>Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline. J Clin Oncol 2007;25:1596&#8211;605.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.10.1949>10.1200/JCO.2006.10.1949</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_9</td><td>BibArticle</td><td>Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566&#8211;77.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00009>10.7326/0003-4819-132-7-200004040-00009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_9</td><td>BibArticle</td><td>Loblaw DA, Mendelson DS, Talcott JA, et al. American society of clinical oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927&#8211;41.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.04.579>10.1200/JCO.2004.04.579</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_9</td><td>BibArticle</td><td>Prostate Cancer Trialists&#8217; Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(00)02163-2>10.1016/S0140-6736(00)02163-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_9</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Akaza</span> <span style='background:#DDDDDD'>H</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hinotsu</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Usami</span> <span style='background:#DDDDDD'>M</span></span>, et al.</aug> <span style='background:#FF9933'>Extended analyses: Combined androgen blockade (CAB) therapy with bicalutamide vs. leuteinizing hormone-releasing hormone agonist (LHRHa) monotherapy in Japanese men with untreated advanced prostate cancer</span>. In: <span style='background:#FFD9B3'>American society of clinical oncology Annual Meeting</span>. <span style='background:#C0FFC0'>Chicago, IL</span>; <span style='background:#66FF66'>2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR36_9</td><td>BibArticle</td><td>Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437&#8211;46.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(10)60172-9>10.1016/S0140-6736(10)60172-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_9</td><td>BibArticle</td><td>Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4:236&#8211;44.</td><td><a href=http://dx.doi.org/10.1038/ncponc0765>10.1038/ncponc0765</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_9</td><td>BibArticle</td><td>Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int 2008;101:271&#8211;4.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2007.07236.x>10.1111/j.1464-410X.2007.07236.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_9</td><td>BibArticle</td><td>Hsieh AC, Ryan CJ. Novel concepts in androgen receptor blockade. Cancer J 2008;14:11&#8211;4.</td><td><a href=http://dx.doi.org/10.1097/PPO.0b013e318161d13e>10.1097/PPO.0b013e318161d13e</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_9</td><td>BibArticle</td><td>Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005;23:8212&#8211;8.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.03.2557>10.1200/JCO.2005.03.2557</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_9</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Miller</span> <span style='background:#DDDDDD'>K</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Steiner</span> <span style='background:#DDDDDD'>U</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lingnau</span> <span style='background:#DDDDDD'>A</span></span>, et al.</aug> <span style='background:#FF9933'>Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer</span>. In: <span style='background:#FFD9B3'>American society of clinical oncology Annual Meeting</span>. <span style='background:#C0FFC0'>Chicago, IL</span>; <span style='background:#66FF66'>2007</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR42_9</td><td>BibArticle</td><td>Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984&#8211;90.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.06.4246>10.1200/JCO.2006.06.4246</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_9</td><td>BibArticle</td><td>Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68&#8211;80.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2007.09.002>10.1016/j.eururo.2007.09.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_9</td><td>BibArticle</td><td>Mostaghel EA, Montgomery RB, Lin DW. The basic biochemistry and molecular events of hormone therapy. Curr Urol Rep 2007;8:224&#8211;32.</td><td><a href=http://dx.doi.org/10.1007/s11934-007-0010-z>10.1007/s11934-007-0010-z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_9</td><td>BibArticle</td><td>Sharifi N, Dahut W, Figg WD. The genetics of castration-resistant prostate cancer: What can the germline tell us? Clin Cancer Res 2008;14:4691&#8211;3.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-08-0453>10.1158/1078-0432.CCR-08-0453</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_9</td><td>BibArticle</td><td>Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842&#8211;7.</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.13.6804>10.1200/JCO.2007.13.6804</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_9</td><td>BibArticle</td><td>Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR48_9</td><td>BibArticle</td><td>Evaul K, Li R, Papari-Zareei M, Auchus RJ, and Sharifi N. 3&#946;-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology. 2010. In press.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR49_9</td><td>BibArticle</td><td>de Launoit Y, Adamski J. Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome. J Mol Endocrinol 1999;22:227&#8211;40.</td><td><a href=http://dx.doi.org/10.1677/jme.0.0220227>10.1677/jme.0.0220227</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_9</td><td>BibArticle</td><td>Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312&#8211;8.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-4118>10.1158/1078-0432.CCR-07-4118</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_9</td><td>BibArticle</td><td>Smith NF, Marsh S, Scott-Horton TJ, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76&#8211;82.</td><td><a href=http://dx.doi.org/10.1038/sj.clpt.6100011>10.1038/sj.clpt.6100011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_9</td><td>BibArticle</td><td>Sharifi N, Hamada A, Sissung T, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008;102:617&#8211;621.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2008.07629.x>10.1111/j.1464-410X.2008.07629.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>